Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRNS shares.
View MRNS analyst ratings or view top-rated stocks.

6 brokerages have issued 1 year price objectives for Marinus Pharmaceuticals' shares. Their MRNS share price forecasts range from $18.00 to $42.00. On average, they anticipate the company's stock price to reach $26.29 in the next year. This suggests a possible upside of 243.2% from the stock's current price.
View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts.

Marinus Pharmaceuticals' stock was trading at $3.98 at the beginning of 2023. Since then, MRNS stock has increased by 92.5% and is now trading at $7.66.
View the best growth stocks for 2023 here.

Marinus Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,830,000 shares, an increase of 19.6% from the April 30th total of 1,530,000 shares. Based on an average trading volume of 630,600 shares, the short-interest ratio is currently 2.9 days.
View Marinus Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our MRNS earnings forecast.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.23. The biopharmaceutical company had revenue of $10.11 million for the quarter, compared to analyst estimates of $2.32 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 179.11% and a negative net margin of 169.99%. During the same quarter in the prior year, the business earned ($0.51) EPS.

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), iShares Biotechnology ETF (IBB),

Marinus Pharmaceuticals's stock reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO).

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Suvretta Capital Management LLC (9.56%), AIGH Capital Management LLC (2.64%), GMT Capital Corp (2.38%), BlackRock Inc. (2.27%), Franklin Resources Inc. (2.07%) and Assenagon Asset Management S.A. (1.37%).
View institutional ownership trends.

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRNS stock can currently be purchased for approximately $7.66.

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $387.21 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 113 workers across the globe.

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565.